FDA warns compounding pharmacy over sterility of GLP-1 drugs
The agency's action targets sterility practices at a pharmacy producing compounded versions of the incretin drugs.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 24 21:58 ETSource: KING5.com
The wire
- 01FDA issued a warning letter to a compounding pharmacy citing sterility concerns with its compounded GLP-1 preparations, according to the report.
- 02Sterility findings at compounders are the main safety lever regulators have used against the compounded incretin market that telehealth prescribers rely on.
- 03Details of the pharmacy's response, any recall and whether product reached patients were not spelled out in the report.
From the source
Read at king5.comFDA warns compounding pharmacy over sterility of GLP-1 drugs
